Features
Episcleral Venous Pressure and Flow
Understanding how EVP affects intraocular pressure may lead to more targeted treatments.
By Abdelrahman M. Elhusseiny, MD, Osamah J. Saeedi, MD
Pathology and Management of Neovascular Glaucoma
Multidisciplinary care is key to optimal outcomes.
By Connie M. Wu, MD
The Importance of Genetic Biomarkers for Glaucoma
Continuing research may improve early identification and intervention for primary open-angle glaucoma.
By Brandon Minh Le, Louis R. Pasquale, MD
Changes in Glaucoma Management Following Diurnal Home Tonometry
A subset of patients can benefit from routine IOP measurements at home.
By Anna Do, MD, Joseph F. Panarelli, MD
Web Exclusives
Treatment of Severe Ocular Surface Disease in the Glaucoma Patient
A variety of options can reduce discomfort.
By Laura Voicu, MD, Sarwat Salim, MD, FACS
Departments
From the Editor: A Love Letter to Latanoprost
By Nathan M. Radcliffe, MD
Glaucoma Myth Busters: Myths About Prostaglandin Analogues and Inflammation
Existing research does not show an association.
By Khin P. Kilgore, MD, Jason D. Jensen, MD, Sean J. McCafferty, MD
Product Spotlight: The World's First Bladeless Goniotomy Device Debuts
The Sion Surgical Instrument was designed to facilitate smooth and gentle goniotomy.
By Karen Appold, contributing writer
Coding: What's New in 2023 Related to Glaucoma
Major cuts to reimbursement have been avoided.
By Kevin J. Corcoran, COE, CPC, CPMA, FNAO
News
Next-generation YAG/SLT Tango Reflex Neo by Ellex Launched
By Conni Koury, contributing editor
FDA Accepts NDA for MydCombi Delivered via Optejet
By Conni Koury, contributing editor
Results for iDose TR Exchange Trial Show Good Safety and Tolerability
By Conni Koury, contributing editor
Phase 2b Study of MediPrint Proprietary Drug-Eluting Contact Lens for Glaucoma Initiated
By Conni Koury, contributing editor
Positive Phase 3 Results for TearClear's Proprietary Preservative-free Latanoprost
By Conni Koury, contributing editor
Salvat Laboratories Submits NDA for Clobetasol Nanoemulsion
By Conni Koury, contributing editor
Visiox Submits NDA for First Once-daily Brimonidine
By Conni Koury, contributing editor
Ocuphire Submits NDA for Nyxol Eye Drops for Mydriasis Reversal
By Conni Koury, contributing editor
Six-year Results from LiGHT Trial Confirm SLT's Safety, Efficacy
By Conni Koury, contributing editor
Omni Surgical System Data From Five Sites Published
By Conni Koury, contributing editor
Two-handed MIGS Possible With Gonio Ready
By Conni Koury, contributing editor
Comparison of Second GDD vs CPC Favored the Latter
By Conni Koury, contributing editor
Review Finds Substantial Research Gaps for Inequities in Eye Care
By Conni Koury, contributing editor
US Ophthalmology Residency Programs Rank Last in Diversity
By Conni Koury, contributing editor
Six-month Data Presented for SpyGlass Drug-eluting IOL
By Conni Koury, contributing editor